GPRC5D-CD3 Bispecific Antibody Layout for Safer T-Cell Killing
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current cancer treatment methods for multiple myeloma, such as chemotherapy and targeting drugs, often cause myelosuppression and have suboptimal efficacy, with a high relapse rate, necessitating the development of novel T cell bispecific antibodies with high efficiency and low toxicity, particularly targeting GPRC5D for effective tumor cell killing.
Innovation Solution
A bispecific antigen-binding molecule is designed with a specific form where a binding moiety sandwiched between binding moieties and an Fc structure, reducing non-specific cytokine release, comprising polypeptides that target GPRC5D and CD3 to recruit T cells to tumor sites and enhance cytotoxic effects.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If conventional chemotherapy or targeting drugs are used to treat multiple myeloma, then the disease condition can be relieved, but myelosuppression occurs and efficacy remains suboptimal with high relapse rate
Solution Approach 1:
The antibody molecule is divided into distinct functional domains: variable regions for antigen recognition (GPRC5D and CD3), constant regions for effector functions, and hinge regions for flexibility. This segmentation allows independent optimization of each function - antigen binding specificity, T cell recruitment, and cytotoxic effector activation - while minimizing off-target effects and myelosuppression
Solution Approach 2:
The bispecific antibody serves multiple functions simultaneously: it binds to GPRC5D on tumor cells for specific recognition, recruits T cells through CD3 binding, activates complement system via Fc region, and mediates antibody-dependent cellular cytotoxicity (ADCC). This multi-functionality consolidates multiple therapeutic mechanisms into a single agent, improving efficacy while reducing the need for combination therapies that increase toxicity
2Productivity
If T cell-based therapies are developed to improve anti-tumor effects, then tumor cell killing efficiency increases, but safety challenges arise due to non-specific cytokine release
Solution Approach 1:
The antibody structure is designed with localized functional regions: the variable regions provide highly specific antigen binding to GPRC5D on tumor cells, ensuring that T cell recruitment and cytokine release are confined to the tumor microenvironment. The CD3-binding region is positioned to engage T cells only when the antibody is bound to the tumor antigen, creating a localized immunological synapse that prevents systemic cytokine storm
Solution Approach 2:
The bispecific antibody acts as an intermediary molecule that bridges tumor cells and T cells through its dual antigen-binding capabilities. By requiring simultaneous binding to both GPRC5D on tumor cells and CD3 on T cells, the antibody ensures that T cell activation and subsequent cytokine release occur only at the tumor site, preventing non-specific systemic activation
3Reliability
If bispecific antibodies targeting CD3 are used to recruit T cells, then specific killing effect is achieved, but balancing anti-tumor activity and safety remains challenging
Solution Approach 1:
The antibody design incorporates specific parameter optimizations: affinity constants for GPRC5D and CD3 binding are tuned to achieve appropriate binding strength without excessive activation; the isotype is selected (IgG1 or IgG2) to modulate Fc-mediated effector functions; amino acid substitutions in the Fc region (e.g., L234A, L235A, N297Q) are introduced to reduce complement activation and ADCC to appropriate levels, preventing excessive toxicity while maintaining anti-tumor activity
Data Source
Figure 1~2B
Figure 2C~3B
Figure 3C~3E
AI summary
The present disclosure provides a form of a bispecific antigen binding molecule, and further provides a bispecific antigen binding molecule for GPRC5D and CD3 which is constructed on the basis of the form, a specific antigen binding molecule for GPRC5D or an antigen binding fragment thereof, a pharmaceutical composition containing the specific antigen binding molecule or the antigen binding fragment thereof, and a related use thereof in treatment of tumors.